Clinical Trials
13 trialsNCT06379217 2026-06-03
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Novartis
Phase 1 Active not recruiting
NCT04720157 2026-05-27
PSMAddition
Novartis
Phase 3 Active not recruiting
NCT05849298 2026-05-27
PSMACare
Novartis
Phase 2 Active not recruiting
NCT03582774 2026-05-26
PSMA SRT
Jonsson Comprehensive Cancer Center
Phase 3 Active not recruiting
NCT04716725 2026-05-15
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT05114746 2026-05-08
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan
Novartis
Phase 2 Completed
NCT04597411 2026-04-30
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
Endocyte
Phase 1 Active not recruiting
NCT05983198 2026-04-29
SatisfACtion
Novartis
Phase 1/2 Active not recruiting
NCT07117760 2026-04-29
Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
First Affiliated Hospital of Fujian Medical University
Phase 1/2 Active not recruiting
NCT05562791 2026-04-22
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT06044857 2026-04-14
PSMA PET Response Guided SabR in High Risk Pca
University of Texas Southwestern Medical Center
Phase 1 Recruiting
NCT04886986 2026-03-31
Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
Weill Medical College of Cornell University
Phase 1 Active not recruiting
NCT04689828 2026-03-23
PSMAfore
Novartis
Phase 3 Active not recruiting